The use of evidence-based medications such as antiplatelets, statins, β-blockers, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) has been reported to reduce the risk of recurrent nonfatal and fatal disease in patients with CHD (Hamm et al., 2011; Smith et al., 2011). This evidence concerns the gene ACE and coronary artery disorder.